TickerLeague

Free Cash Flow for Insulet (PODD)

Free Cash Flow for Insulet (PODD): headline value $377.70M · YoY +23.7%. Annual and quarterly series, chart, and tables are below.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

Latest period

$377.70M

YoY change

+23.7%

5Y CAGR

N/A

Peak year (2025)

$377.70M

Latest annual

$377.70M

Free Cash Flow history chart for Insulet (PODD) from 2004 to 2025

Free Cash Flow history table for Insulet (PODD) from 2004 to 2025

Fiscal yearPeriod endedReportedFree Cash FlowYoY
2025$377.70M+23.7%
2024$305.40M+335.7%
2023$70.10M-283.0%
2022-$38.30M-79.9%
2021-$190.80M+131.3%
2020-$82.50M+13.8%
2019-$72.50M-42.7%
2018-$126.45M+251.1%
2017-$36.02M+480.6%
2016-$6.20M-73.2%
2015-$23.16M+802.6%
2014-$2.57M-35.2%
2013-$3.96M-90.1%
2012-$40.05M+9.5%
2011-$36.57M-13.3%
2010-$42.17M-19.6%
2009-$52.46M-43.4%
2008-$92.66M+53.3%
2007-$60.46M+34.5%
2006-$44.96M+74.3%
2005-$25.79M+63.6%
2004-$15.76M

Free Cash Flow values are taken from Insulet's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

Analysis

2025's annual free cash flow for Insulet (PODD) came in at $377.70M – grew 23.7% year-over-year.

The dataset's maximum free cash flow sits at $377.70M (2025); the minimum reading of -$190.80M dates to 2021.

Among 8 Healthcare peers, Insulet (PODD) ranks 9th; the peer median for free cash flow is $14.22B.

Insulet Free Cash Flow by Year

Insulet Free Cash Flow 2025: $377.70M

Insulet free cash flow in 2025 was $377.70M, grew 23.7% from 2024. This figure represents the highest annual value in the available history.

Insulet Free Cash Flow 2024: $305.40M

Insulet free cash flow in 2024 was $305.40M, surged 335.7% from 2023.

Insulet Free Cash Flow 2023: $70.10M

Insulet free cash flow in 2023 was $70.10M, plunged 283.0% below 2022.

Insulet Free Cash Flow 2022: -$38.30M

Insulet free cash flow in 2022 was -$38.30M, plunged 79.9% below 2021.

Insulet Free Cash Flow 2021: -$190.80M

Insulet free cash flow in 2021 was -$190.80M.

See more financial history for Insulet (PODD).

Sector peers — Free Cash Flow

Companies in the same sector as Insulet, ranked by their latest free cash flow.

CompanyFree Cash FlowSector
Novo Nordisk A/S (NVO)$28.99BHealthcare
Johnson & Johnson (JNJ)$19.70BHealthcare
AbbVie Inc. (ABBV)$17.82BHealthcare
UnitedHealth Group Incorporated (UNH)$16.07BHealthcare
Merck & Co., Inc. (MRK)$12.36BHealthcare
AstraZeneca PLC (AZN)$11.77BHealthcare
Eli Lilly and Company (LLY)$8.97BHealthcare
Amgen Inc. (AMGN)$8.10BHealthcare

Frequently asked questions

What is Insulet's free cash flow?

Latest reported free cash flow for Insulet (PODD) is $377.70M (period ending December 31, 2025).

How has Insulet free cash flow changed year-over-year?

Insulet (PODD) free cash flow changed +23.7% year-over-year on the latest annual filing.

When did Insulet free cash flow hit its highest annual value?

Insulet free cash flow reached its highest annual value of $377.70M in 2025.

What was Insulet free cash flow in 2024?

Insulet (PODD) free cash flow in 2024 was $305.40M.

What was Insulet free cash flow in 2025?

Insulet (PODD) free cash flow in 2025 was $377.70M.

Metrics overview

Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.